Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
Keizo Takemi, a veteran lawmaker from Japan’s ruling Liberal Democratic Party (LDP), is seeking a sixth term in the upcoming Upper House election. The former health minister says he will draw on his experience at the ministry to boost infrastructure…
To read the full story
Related Article
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback
July 23, 2025
- Japan’s Ruling Bloc Routed in Upper House Poll; Takemi to Retire, Furukawa, Kamayachi, and Honda Secure Seats
July 22, 2025
- Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
July 14, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
July 3, 2025
REGULATORY
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
June 17, 2026
- Minister Signals Chuikyo Review of Innovation Incentives after Roadmap
June 17, 2026
- MHLW Issues Guidance on Proper Use of GLP-1 Drugs
June 17, 2026
- Japan Panel Seeks Easing of Rules on Radiopharma Research Samples
June 16, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…